keyword
MENU ▼
Read by QxMD icon Read
search

Antidepressant efficacy

keyword
https://www.readbyqxmd.com/read/28231069/the-potential-of-transcranial-photobiomodulation-therapy-for-treatment-of-major-depressive-disorder
#1
Farzad Salehpour, Seyed Hossein Rasta
Major depressive disorder is a common debilitating mood disorder that affects quality of life. Prefrontal cortex abnormalities, an imbalance in neurotransmitters, neuroinflammation, and mitochondrial dysfunction are the major factors in the etiology of major depressive disorder. Despite the efficacy of pharmacotherapy in the treatment of major depressive disorder, 30%-40% of patients do not respond to antidepressants. Given this, exploring the alternative therapies for treatment or prevention of major depressive disorder has aroused interest among scientists...
February 23, 2017: Reviews in the Neurosciences
https://www.readbyqxmd.com/read/28230414/the-effect-of-cognitive-behavioral-therapy-as-an-antidepressive-treatment-is-falling-reply-to-lj%C3%A3-tsson-et-al-2017-and-cristea-et-al-2017
#2
Oddgeir Friborg, Tom J Johnsen
This article critically reassesses the nonlinear reanalysis by Ljótsson, Hedman, Mattsson, and Andersson (2017) and reviews Cristea et al.'s (2017) extension of our original meta-analysis (Johnsen & Friborg, 2015) reporting a decline in the effects of cognitive-behavioral therapy (CBT) for treating unipolar depression. Ljótsson et al. fitted a piecewise meta-regression model to the data, indicating a halt in the decline from the year 1995 onward, hence concluding that CBT is not gradually losing its efficacy...
March 2017: Psychological Bulletin
https://www.readbyqxmd.com/read/28229112/chronic-psychosocial-stressors-in-adulthood-studies-in-mice-rats-and-tree-shrews
#3
REVIEW
Christopher R Pryce, Eberhard Fuchs
Human psychological stress is the major environmental risk factor for major depression and certain of the anxiety disorders. Psychological stressors often occur in the context of the adult social environment, and they or the memory formed of them impact on the individual across an extended period, thereby constituting chronic psychosocial stress (CPS). Psychosocial stressors often involve loss to the individual, such as the ending of a social relationship or the onset of interpersonal conflict leading to loss of social control and predictability...
February 2017: Neurobiology of Stress
https://www.readbyqxmd.com/read/28228056/brexpiprazole
#4
Marija Markovic, Alyssa Gallipani, Krina H Patel, Megan Maroney
OBJECTIVE: To review the pharmacology and clinical data for brexpiprazole in schizophrenia and major depressive disorder (MDD). DATA SOURCES: An English-language literature search using PubMed and MEDLINE was performed using the term brexpiprazole. All articles containing human clinical trial data published up to September 2016 were evaluated for inclusion as well as information from the manufacturer's product labeling. STUDY SELECTION/DATA EXTRACTION: Phase 3 trials for brexpiprazole were evaluated...
April 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/28225699/what-is-the-relevance-of-procedural-fairness-to-making-determinations-about-medical-evidence
#5
Govind Persad
Approaches relying on fair procedures rather than substantive principles have been proposed for answering dilemmas in medical ethics and health policy. These dilemmas generally involve two questions: the epistemological (factual) question of which benefits an intervention will have, and the ethical (value) question of how to distribute those benefits. This article focuses on the potential of fair procedures to help address epistemological and factual questions in medicine, using the debate over antidepressant efficacy as a test case...
February 1, 2017: AMA Journal of Ethics
https://www.readbyqxmd.com/read/28222534/a-meta-analysis-of-memantine-for%C3%A2-depression
#6
Taro Kishi, Shinji Matsunaga, Nakao Iwata
We conducted a systematic review and meta-analysis on whether memantine was beneficial for the treatment of depressive symptoms in major depressive disorder (MDD) and bipolar disorder (BD). The analysis included double-blind, randomized, placebo-controlled trials of memantine in MDD and BD. The primary outcome measures for efficacy and safety were response rate and all-cause discontinuation, respectively. Risk ratio (RR) and standardized mean difference with 95% confidence intervals (95% CI) were calculated...
February 10, 2017: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/28216196/hypericum-perforatum-st-john-s-wort-beyond-depression-a-therapeutic-perspective-for-pain-conditions
#7
REVIEW
Nicoletta Galeotti
ETHNOPHARMACOLOGICAL RELEVANCE: Hypericum perforatum L. (Hypericaceae), popularly called St. John's wort (SJW), has a rich historical background being one of the oldest used and most extensively investigated medicinal herbs. Many bioactivities and applications of SJW are listed in popular and in scientific literature, including antibacterial, antiviral, anti-inflammatory. In the last three decades many studies focused on the antidepressant activity of SJW extracts. However, several studies in recent years also described the antinociceptive and analgesic properties of SJW that validate the traditional uses of the plant in pain conditions...
February 12, 2017: Journal of Ethnopharmacology
https://www.readbyqxmd.com/read/28213170/non-response-at-week-4-as-clinically-useful-indicator-for-antidepressant-combination-in-major-depressive-disorder-a-sequential-rct
#8
Masaki Kato, Yoshiteru Takekita, Yosuke Koshikawa, Shiho Sakai, Hiroki Bandou, Keiichiro Nishida, Naotaka Sunada, Ai Onohara, Yoshiyuki Hatashita, Alessandro Serretti, Toshihiko Kinoshita
We aimed to compare the efficacy and tolerability of mirtazapine versus SSRIs and to assess whether "non-response at week 4" may be a clinical indicator for combining mirtazapine and SSRIs for subsequent treatment. One-hundred fifty-four outpatients with MDD were randomized to receive mirtazapine or SSRIs in step I (4 weeks). Non-responders in step I were randomly assigned to either mirtazapine or SSRIs monotherapy or their combination in step IIa while responders in step I continued the same monotherapy in step IIb for 4 weeks...
February 3, 2017: Journal of Psychiatric Research
https://www.readbyqxmd.com/read/28197000/impact-of-an-educational-module-in-antidepressant-naive-patients-prescribed-antidepressants-for-depression-pilot-proof-of-concept-randomized-controlled-trial
#9
Annie P John, Nagendra Madan Singh, Nagarajaiah, Chittaranjan Andrade
BACKGROUND: Patients are educated about their illness and its treatment at the time of diagnosis. However, little is known about how much of this education is retained and how it influences knowledge about, attitudes toward, and experiences with medication in antidepressant-naive patients with depression. METHODS: Antidepressant-naive outpatients with International Classification of Diseases-10 dysthymia or mild to moderate depression, who were advised antidepressant monotherapy, were randomized to control (n = 22) or intervention (n = 17) groups...
October 2016: Indian Journal of Psychiatry
https://www.readbyqxmd.com/read/28194724/ketamine-and-beyond-investigations-into-the-potential-of-glutamatergic-agents-to-treat-depression
#10
REVIEW
Marc S Lener, Bashkim Kadriu, Carlos A Zarate
Clinical and preclinical studies suggest that dysfunction of the glutamatergic system is implicated in mood disorders such as major depressive disorder and bipolar depression. In clinical studies of individuals with major depressive disorder and bipolar depression, rapid reductions in depressive symptoms have been observed in response to subanesthetic-dose ketamine, an agent whose mechanism of action involves the modulation of glutamatergic signaling. The findings from these studies have prompted the repurposing and/or development of other glutamatergic modulators for antidepressant efficacy, both as monotherapy or as an adjunct to conventional monoaminergic antidepressants...
February 14, 2017: Drugs
https://www.readbyqxmd.com/read/28192737/a-systematic-review-of-yoga-for-major-depressive-disorder
#11
REVIEW
Holger Cramer, Dennis Anheyer, Romy Lauche, Gustav Dobos
BACKGROUND: The purpose of this review was to investigate the efficacy and safety of yoga interventions in treating patients with major depressive disorder. METHODS: MEDLINE, Scopus, and the Cochrane Library were screened through December 2016. Randomized controlled trials (RCTs) comparing yoga to inactive or active comparators in patients with major depressive disorder were eligible. Primary outcomes included remission rates and severity of depression. Anxiety and adverse events were secondary outcomes...
February 7, 2017: Journal of Affective Disorders
https://www.readbyqxmd.com/read/28190661/the-novel-antipsychotic-drug-brexpiprazole-alone-and-in-combination-with-escitalopram-facilitates-prefrontal-glutamatergic-transmission-via-a-dopamine-d1-receptor-dependent-mechanism
#12
Carl Björkholm, Monica M Marcus, Åsa Konradsson-Geuken, Kent Jardemark, Torgny H Svensson
Brexpiprazole (Rexulti(®)), a novel D2/3 receptor (R) partial agonist, was recently approved as monotherapy for schizophrenia, demonstrating effectiveness against both positive and negative symptoms, and also approved as add-on treatment to antidepressant drugs, inducing a potent antidepressant effect with a faster onset compared to an antidepressant given alone. Moreover, brexpiprazole has demonstrated pro-cognitive effects in preclinical studies. To explore whether the observed effects may be mediated via modulation of prefrontal glutamatergic transmission, we investigated the effect of brexpiprazole, alone and in combination with the SSRI escitalopram, on prefrontal glutamatergic transmission using in vitro electrophysiological intracellular recordings of deep layer pyramidal cells of the rat medial prefrontal cortex (mPFC)...
February 9, 2017: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28179816/sex-differences-in-the-psychopharmacological-treatment-of-depression
#13
John J Sramek, Michael F Murphy, Neal R Cutler
Although a number of studies have observed that females respond better to serotonergic antidepressants than males and that postmenopausal females have a diminished response to antidepressants compared with younger females, there are also studies that conflict with both of these findings, making any generalizations regarding sex differences difficult to make. Sex variance in antidepressant efficacy and pharmacokinetics profiles have been attributed to sex-based physiological differences, behavioral differences, related disorders, and sex-specific conditions, including pregnancy and menopause...
December 2016: Dialogues in Clinical Neuroscience
https://www.readbyqxmd.com/read/28177953/double-blind-switch-study-of-vilazodone-in-the-treatment-of-major-depressive-disorder
#14
Jon E Grant, Sarah A Redden, Eric W Leppink
Approximately 40% of patients treated for depression do not respond to a trial of an antidepressant. The aim of the proposed study was to evaluate the efficacy and safety of switching to vilazodone in patients with major depressive disorder who are unresponsive or only partially responsive to a trial of citalopram. Seventy-nine adults with major depressive disorder were enrolled in an open-label study of citalopram (20 mg/day) for 6 weeks. Those still symptomatic after 6-weeks of citalopram were randomly assigned to either a higher dose of citalopram (40 mg/day) or to vilazodone in a double-blind trial for 6 weeks...
February 7, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28159590/pharmacogenetics-of-antidepressant-response-a-polygenic-approach
#15
Judit García-González, Katherine E Tansey, Joanna Hauser, Neven Henigsberg, Wolfgang Maier, Ole Mors, Anna Placentino, Marcella Rietschel, Daniel Souery, Tina Žagar, Piotr M Czerski, Borut Jerman, Henriette N Buttenschøn, Thomas G Schulze, Astrid Zobel, Anne Farmer, Katherine J Aitchison, Ian Craig, Peter McGuffin, Michel Giupponi, Nader Perroud, Guido Bondolfi, David Evans, Michael O'Donovan, Tim J Peters, Jens R Wendland, Glyn Lewis, Shitij Kapur, Roy Perlis, Volker Arolt, Katharina Domschke, Gerome Breen, Charles Curtis, Lee Sang-Hyuk, Carol Kan, Stephen Newhouse, Hamel Patel, Bernhard T Baune, Rudolf Uher, Cathryn M Lewis, Chiara Fabbri
BACKGROUND: Major depressive disorder (MDD) has a high personal and socio-economic burden and >60% of patients fail to achieve remission with the first antidepressant. The biological mechanisms behind antidepressant response are only partially known but genetic factors play a relevant role. A combined predictor across genetic variants may be useful to investigate this complex trait. METHODS: Polygenic risk scores (PRS) were used to estimate multi-allelic contribution to: 1) antidepressant efficacy; 2) its overlap with MDD and schizophrenia...
January 31, 2017: Progress in Neuro-psychopharmacology & Biological Psychiatry
https://www.readbyqxmd.com/read/28150971/effects-of-bupropion-sustained-release-on-task-related-eeg-alpha-activity-in-smokers-individual-differences-in-drug-response
#16
Jian Zhu, Ryan P Coppens, Norka E Rabinovich, David G Gilbert
The mechanisms underlying bupropion's efficacy as an antidepressant and a smoking cessation aid are far from being fully characterized. The present study is the first to examine the effects of bupropion on visuospatial task-related parietal EEG alpha power asymmetry-an asymmetry that has previously been found to be associated with severity of depressive symptoms (i.e., the more depressive symptoms, the greater alpha power in the right vs. left parietal area [Henriques & Davidson, 1997; Rabe, Debener, Brocke, & Beauducel, 2005])...
February 2017: Experimental and Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28149320/antidepressive-response-of-inpatients-with-major-depression-to-adjuvant-occupational-therapy-a-case-control-study
#17
Marc-Andreas Edel, Brian Blackwell, Markus Schaub, Barbara Emons, Tanja Fox, Friederike Tornau, Bernward Vieten, Patrik Roser, Ida Sibylle Haussleiter, Georg Juckel
BACKGROUND: Despite marked costs and limited evidence regarding effectiveness, occupational therapy (OT) is widely applied in psychiatric settings and financed by health insurance companies in European countries. This pilot study investigated the antidepressive effects of adjuvant OT for patients with major depression in a 6-week inpatient setting, stratified for females and males. METHODS: A total of 114 inpatients with major depression were assigned to either a standard OT group (using basic handcraft) or an active control group that played board games (2 h daily, 5 days a week)...
2017: Annals of General Psychiatry
https://www.readbyqxmd.com/read/28146251/effect-of-disorder-specific-vs-nonspecific-psychotherapy-for-chronic-depression-a-randomized-clinical-trial
#18
Elisabeth Schramm, Levente Kriston, Ingo Zobel, Josef Bailer, Katrin Wambach, Matthias Backenstrass, Jan Philipp Klein, Dieter Schoepf, Knut Schnell, Antje Gumz, Paul Bausch, Thomas Fangmeier, Ramona Meister, Mathias Berger, Martin Hautzinger, Martin Härter
Importance: Chronic depression is a highly prevalent and disabling disorder. There is a recognized need to assess the value of long-term disorder-specific psychotherapy. Objective: To evaluate the efficacy of the Cognitive Behavioral Analysis System of Psychotherapy (CBASP) compared with that of nonspecific supportive psychotherapy (SP). Design, Setting, and Participants: A prospective, multicenter, evaluator-blinded, randomized clinical trial was conducted among adult outpatients with early-onset chronic depression who were not taking antidepressant medication...
February 1, 2017: JAMA Psychiatry
https://www.readbyqxmd.com/read/28128336/prophylactic-ketamine-attenuates-learned-fear
#19
Josephine C McGowan, Christina T LaGamma, Sean C Lim, Melina Tsitsiklis, Yuval Neria, Rebecca A Brachman, Christine A Denny
Ketamine has been reported to be an efficacious antidepressant for major depressive disorder (MDD) and posttraumatic stress disorder (PTSD). Most recently, ketamine has also been shown to be prophylactic against stress-induced depressive-like behavior in mice. It remains unknown, however, when ketamine should be administered relative to a stressor in order to maximize its antidepressant and/or prophylactic effects. Moreover, it is unknown if ketamine can be prophylactic against subsequent stressors. We systematically administered ketamine at different time points relative to a fear experience in order to determine when ketamine is most effective at reducing fear expression or preventing fear reactivation...
January 27, 2017: Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28119076/spinal-astrocytic-c-jun-n-terminal-kinase-jnk-activation-as-counteracting-mechanism-to-the-amitriptyline-analgesic-efficacy-in-painful-peripheral-neuropathies
#20
Maria Domenica Sanna, Carla Ghelardini, Nicoletta Galeotti
Several drugs and agents are currently used for the treatment of neuropathic pain. Among them amitriptyline, a tricyclic antidepressant drug, represent a first line treatment. Despite its well-documented clinical efficacy, amitriptyline is ineffective in some animal models of neuropathic pain. The aim of this study was to investigate into amitriptyline poor efficacy in neuropathic pain and to determine the role of c-Jun N-terminal kinase (JNK) activation as counteracting mechanism to the analgesic effects of this drug...
January 21, 2017: European Journal of Pharmacology
keyword
keyword
62561
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"